Introduction
The U.S. Food and Drug Administration (FDA) has recently announced its plan to reduce and eventually replace animal testing requirements for monoclonal antibody therapies, and eventually, other drug products. This initiative is part of FDA’s commitment to advancing New Approach Methodologies (NAMs) as alternatives to traditional animal studies. Developers of therapeutic antibodies may be wondering how this change impacts their nonclinical testing strategy. Having a trusted regulatory advisor to help integrate NAMs, including in vitro and in silico approaches into the overall nonclinical strategy, will be critical as FDA continues to evolve its expectations over the next few years. Biologics Consulting brings together seasoned experts in drug development who can help with the challenges of adapting to, and implementing, new test methods.
Our Approach
As a first step, we have engaged with contract research organizations (CROs) regarding their perspectives on FDA’s roadmap for NAMs and their plans for developing alternative methods for assessing the safety of candidate drug products. Then, once the CROs have clarity on their NAMs capabilities and ensure that they can support developers in meeting the new regulatory expectations, it will be important to ask the right questions, particularly regarding the validation, timelines, implementation, and human relevance of specific NAMs. These considerations will be critical when integrating NAMs into a nonclinical safety assessment strategy. Given that NAMs encompass novel assays and technologies that are not yet standardized, comprehensive protocol review, study oversight, and interpretation of findings and conclusions will be imperative. Therefore, close collaboration between the Sponsor and CRO will be needed throughout the study planning, execution, and reporting process. Additionally, it will be important to clearly communicate any limitations of these novel assays and evaluate their potential impact on the overall risk assessment of the candidate drug product. Finally, inclusion of data from these NAMs in regulatory submissions will need to be thoughtfully planned out and clearly summarized for the best chances of success with FDA reviewers, who will also be determining the appropriateness and validity of these new methods alongside regulatory consultants and CRO staff.
How We Can Help
The Biologics Consulting nonclinical pharmacology and toxicology team collaborates closely with testing laboratories on behalf of our clients, whether they are standard animal studies or new approaches, to ensure that study design is appropriately aligned with FDA’s expectations. Given that NAMs is a developing area for both regulators and industry, input from our consultants with a strong track record of successful FDA interactions can help Sponsors anticipate regulatory expectations and support clear communication with the FDA review teams. We have outlined our approach here to provide technical and regulatory support to Sponsors developing monoclonal antibody products in the interim and over the next few years. Our consultants are well-positioned to guide Sponsors through this transition, offering strategic insight and technical expertise to support the adoption of NAMs and ensure regulatory readiness.
